Steroid-sparing effects of methotrexate in systemic lupus erythematosus: A double-blind, randomized, placebo-controlled trial

Arthritis Care and Research

Volumn 59, Issue 12, 2008, Pages 1796-1804

  Fortin, Paul R ^a,g   Abrahamowicz, Michal ^b   Ferland, Diane ^c   Lacaille, Diane ^d   Smith, C Douglas ^e   Zummer, Michel ^f  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d ARTHRITIS RESEARCH CENTRE OF CANADA   (Canada)

^e Ottawa Hospital   (Canada)

^f MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^g MP 10 304 ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; FOLIC ACID; METHOTREXATE; PLACEBO; PREDNISONE;

ARTICLE; CARDIOVASCULAR SYMPTOM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; INFECTION; KIDNEY DISEASE; LONGITUDINAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; NEUROLOGIC DISEASE; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; REVISED SYSTEMIC LUPUS ACTIVITY MEASURE; SCORING SYSTEM; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE;

ADULT; ANTIRHEUMATIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METHOTREXATE; MIDDLE AGED; PREDNISONE; RESEARCH DESIGN; STEROIDS;

EID: 57149118480     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.24068     Document Type: Article

References (24)

1. Kremer JM. Toward a better understanding of methotrexate [review]. Arthritis Rheum 2004;50:1370-82.
2. Davidson JR, Graziano FM, Rothenberg RJ. Methotrexate therapy for severe systemic lupus erythematosus [letter]. Arthritis Rheum 1987;30:1195-6.
3. Rothenberg RJ, Graziano FM, Grandone JT, Goldberg JW, Bjarnason DF, Finesilver AG. The use of methotrexate in steroidresistant systemic lupus erythematosus. Arthritis Rheum 1988;31:612-5.
4. Wilson K, Abeles M. A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1994;21:1674-7.
5. Arfi S, Numeric P, Grollier L, Panelatti G, Jean-Baptiste G. Treatment of corticodependent systemic lupus erythematosus with low-dose methotrexate. Rev Med Interne 1995;16:885-90. In French.
6. Abud-Mendoza C, Sturbaum AK, Vazquez-Compean R, Gonzalez-Amaro R. Methotrexate therapy in childhood systemic lupus erythematosus. J Rheumatol 1993;20:731-3.
7. Wise CM, Vuyyuru S, Roberts WN. Methotrexate in nonrenal lupus and undifferentiated connective tissue disease: a review of 36 patients. J Rheumatol 1996;23:1005-10.
8. Gansauge S, Breitbart A, Rinaldi N, Schwarz-Eywill M. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis 1997;56:382-5.
9. Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1999;26:1275-9.
10. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
11. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum 2004;50:3418-26.
12. Abrahamowicz M, Fortin PR, du Berger R, Nayak V, Neville C, Liang MH. The relationship between disease activity and expert physician's decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials. J Rheumatol 1998;25:277-84.
13. Gladman DD, Urowitz MB. The SLICC/ACR damage index: progress report and experience in the field. Lupus 1999;8:632-7.
14. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000;27:373-6.
15. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
16. Ware JE Jr, Kosinski M. SF-36 physical and mental health summary scales: a manual for users of version 1. 2nd ed. Lincoln (RI): QualityMetric Incorporated; 2001.
17. Fortin PR, Abrahamowicz M, Clarke AE, Neville C, du Berger R, Fraenkel L, et al. Do lupus disease activity measures detect clinically important change? J Rheumatol 2000;27:1421-8.
18. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trial. Biometrics 1979;35:549-56.
19. Bryk T, Raudenbush SW. Hierarchial linear models: applications and data analysis methods. 2nd ed. Thousand Oaks (CA): Sage Publishing; 2001.
20. Molenberghs G, Thijs H, Jansen I, Beunckens C, Kenward MG, Mallinckrodt C, et al. Analyzing incomplete longitudinal clinical trial data. Biostatistics 2004;5:445-64.
21. Waternaux C, Laird NM, Ware JM. Methods for analysis of longitudinal data: blood-lead concentration and cognitive development. J Am Stat Assoc 1989;84:33-41.
22. Chang ER, Abrahamowicz M, Ferland D, Fortin PR. Organ manifestations influence differently the responsiveness of 2 lupus disease activity measures, according to patients' or physicians' evaluations of recent lupus activity. J Rheumatol 2002;29:2350-8.
23. Rosen J, Miner JN. The search for safer glucocorticoid receptor ligands. Endocr Rev 2005;26:452-64.
24. Wilke WS, Krall PL, Scheetz RJ. Methotrexate for systemic lupus erythematosus: a retrospective analysis of 17 unselected cases. Clin Exp Rheumatol 1991;9:581-7.